Eiko Lifesciences Ltd
Eiko Lifesciences Ltd (EIKO) last reported results for the quarter ended Jun 2026, with sales of ₹16.75 crore and net profit of ₹1.51 crore. The stock last traded at ₹48.5, a market capitalisation of ₹71.1 crore, on a P/E of 14.5. Over the past 52 weeks the stock has ranged between ₹43 and ₹64.4. Figures are as of 6 Oct 2026 and are not real time.
Eiko Lifesciences Ltd share price and key metrics
- Current price
- ₹48.5
- Market cap
- ₹71.1 cr
- Stock P/E
- 14.5
- Book value
- ₹48
- ROE
- 8.47%
- ROCE
- 11.1%
- Dividend yield
- 0.00%
- 52w high / low
- 64.4/43.0
Metrics as of 6 Oct 2026. Not real time.
Track Eiko Lifesciences Ltd
Cruxal reads every Eiko Lifesciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Eiko Lifesciences Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 56%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 102%
- 10 Years
- %
- 5 Years
- -8%
- 3 Years
- -7%
- 1 Year
- -7%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- 8%
Eiko Lifesciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹16.75 cr, up 56.4% from ₹10.71 cr a year earlier. Net profit was ₹1.51 cr, up 36.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 8.16 | 7.49 | 11.27 | 10.71 | 11.67 | 11.98 | 18.34 | 16.75 |
| Expenses | 7.73 | 6.86 | 9.95 | 9.2 | 9.9 | 10.1 | 16.08 | 14.82 |
| Operating profit | 0.43 | 0.63 | 1.32 | 1.51 | 1.77 | 1.88 | 2.26 | 1.93 |
| OPM % | 5.27% | 8.41% | 11.71% | 14.10% | 15.17% | 15.69% | 12.32% | 11.52% |
| Other income | 0.13 | 0.12 | 0.64 | 0.27 | 0.3 | 0.35 | 0.13 | 0.45 |
| Interest | 0.04 | 0.03 | 0.07 | 0.05 | 0.1 | 0.07 | 0.12 | 0.13 |
| Depreciation | 0.16 | 0.16 | 0.25 | 0.25 | 0.26 | 0.26 | 0.25 | 0.25 |
| Profit before tax | 0.36 | 0.56 | 1.64 | 1.48 | 1.71 | 1.9 | 2.02 | 2 |
| Tax % | 27.78% | 25.00% | 23.78% | 25.00% | 24.56% | 24.74% | 25.74% | 24.50% |
| Net profit | 0.28 | 0.42 | 1.25 | 1.11 | 1.29 | 1.43 | 1.5 | 1.51 |
| EPS (₹) | 0.22 | 0.33 | 0.84 | 0.66 | 0.79 | 0.88 | 0.91 | 0.91 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Eiko Lifesciences Ltd annual results
| ₹ crore | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
| Sales | 2.36 | 4.27 | 10.4 | 37.66 | 52.57 | 58.74 |
| Operating profit | 0.38 | -0.68 | -4.51 | 2.77 | 7.33 | 7.84 |
| OPM % | 16.10% | -15.93% | -43.37% | 7.36% | 13.94% | 13.35% |
| Net profit | 0.2 | -0.78 | -3.62 | 2.32 | 5.32 | 5.73 |
| EPS (₹) | 0.31 | -0.69 | -2.98 | 1.86 | 3.71 | 3.49 |
TTM is the trailing twelve months to the most recent quarter.
Eiko Lifesciences Ltd balance sheet
| ₹ crore | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity capital | 3.82 | 3.82 | 3.82 | 13.76 | 14.35 |
| Reserves | 1.74 | 1.10 | -0.87 | 43.03 | 54.44 |
| Borrowings | 1.74 | 1.37 | 1.61 | 2.76 | 4.73 |
| Other liabilities | 3.66 | 3.01 | 7.49 | 6.56 | 15.85 |
| Total liabilities | 10.96 | 9.30 | 12.05 | 66.11 | 89.37 |
| Fixed assets | 1.68 | 1.71 | 1.75 | 23.12 | 22.10 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 3.17 | 1.72 | 0.10 | 7.15 | 15.29 |
| Other assets | 6.11 | 5.87 | 10.20 | 35.84 | 51.98 |
| Total assets | 10.96 | 9.30 | 12.05 | 66.11 | 89.37 |
As reported by the company. Total assets equal total liabilities by construction.
Eiko Lifesciences Ltd cash flow
| ₹ crore | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash from operations | 0.00 | 0.16 | -0.33 | 2.78 | 2.25 |
| Cash from investing | 0.00 | -0.30 | -0.71 | -11.30 | -8.63 |
| Cash from financing | 0.00 | -0.55 | 0.95 | 6.96 | 8.21 |
| Net cash flow | 0.00 | -0.69 | -0.09 | -1.57 | 1.83 |
| Free cash flow | 0.00 | -0.04 | -0.56 | -7.51 | 2.25 |
| CFO / operating profit | 0% | -26% | 7% | 112% | 50% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Eiko Lifesciences Ltd operating ratios
| Per year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROCE % | — | -11.83% | -105.39% | — | 11.12% |
| Debtor days | 225.81 | 73.51 | 41.41 | 104.58 | 140.39 |
| Inventory days | 819.93 | 287.76 | 153.96 | 64.48 | 35.09 |
| Days payable | 605.69 | 174.40 | 184.66 | 36.99 | 111.03 |
| Cash conversion cycle | 440.04 | 186.87 | 10.72 | 132.07 | 64.46 |
| Working capital days | 80.42 | -1.71 | -151.62 | 143.73 | 127.89 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Eiko Lifesciences Ltd shareholding pattern
Promoters held 39.91% at Jun 2026, up from 36.74% at Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 24.40% | 31.27% | 36.23% | 36.74% | 37.17% | 37.17% | 39.91% | 39.91% |
| Public | 75.59% | 68.73% | 63.78% | 63.26% | 62.81% | 62.83% | 60.09% | 60.09% |
| No. of shareholders | 3,140 | 3,456 | 3,336 | 3,322 | 3,150 | 3,092 | 2,969 | 3,019 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Eiko Lifesciences Ltd corporate filings
- Pursuant to SEBI (PIT) Regulations, 2015 as amended and as per Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the trading window for dealing ....Insider Trading / SASTlow impact
- Eiko LifeSciences Limited concludes 49th AGM; all resolutions passed including financial adoption and related party transactionsAGM/EGMlow impact
Cruxal's analysis: Eiko LifeSciences Limited has successfully concluded its 49th Annual General Meeting held…
Read the full analysis - Eiko LifeSciences Limited Concludes 49th Annual General Meeting; Approves Financial Statements and Board AppointmentsAGM/EGMlow impact
Cruxal's analysis: Eiko LifeSciences Limited has successfully concluded its 49th Annual General Meeting held…
Read the full analysis - Eiko Lifesciences Limited schedules 49th Annual General Meeting for September 22, 2026Company Updatelow impact
Cruxal's analysis: Eiko Lifesciences Limited has issued a formal notice regarding its 49th Annual General…
Read the full analysis - Eiko Lifesciences Limited Announces 49th Annual General Meeting (AGM) Scheduled for September 22, 2026Company Updatelow impact
Cruxal's analysis: Eiko Lifesciences Limited has issued a formal disclosure regarding its 49th Annual…
Read the full analysis - Eiko Lifesciences Ltd schedules 49th Annual General Meeting for September 22, 2026Otherslow impact
Cruxal's analysis: Eiko Lifesciences has announced that its 49th Annual General Meeting will be held on…
Read the full analysis - Eiko LifeSciences Limited Announces 49th AGM and Seeks Shareholder Approval for Material Related Party TransactionsAGM/EGMmedium impact
Cruxal's analysis: Eiko LifeSciences Limited has issued a notice for its 49th Annual General Meeting…
Read the full analysis - Eiko Lifesciences Limited announces resignation of Independent Director Hasti DoshiCompany Updatelow impact
Cruxal's analysis: Eiko Lifesciences Limited has formally notified the exchange regarding the resignation of…
Read the full analysis - Eiko Lifesciences Limited appoints Mr. Suraj Mahadev Gaikwad as Additional Independent DirectorCompany Updatelow impact
Cruxal's analysis: Eiko Lifesciences Limited has announced the appointment of Mr. Suraj Mahadev Gaikwad as…
Read the full analysis - Eiko LifeSciences Limited Announces Board Reshuffle and Schedules 49th Annual General MeetingOtherslow impact
Cruxal's analysis: Eiko LifeSciences Limited has announced a board-level transition involving the…
Read the full analysis - Eiko Lifesciences Ltd: Submission of routine regulatory disclosure under Regulation 30Company Updatelow impact
Cruxal's analysis: Eiko Lifesciences Ltd has filed a routine disclosure under Regulation 30 of the SEBI…
Read the full analysis - Eiko Lifesciences Ltd allots 305,000 equity shares upon conversion of warrantsCompany Updatelow impact
Cruxal's analysis: Eiko Lifesciences has completed the allotment of 305,000 equity shares following the…
Read the full analysis - Eiko Lifesciences publishes Q1 FY2027 unaudited financial results in newspapersCompany Updatelow impact
Cruxal's analysis: Eiko Lifesciences has fulfilled regulatory requirements under SEBI LODR by publishing its…
Read the full analysis - Eiko LifeSciences Reports Q1 FY27 Consolidated Revenue of 16.75 crore and PAT of 1.51 croreBoard Meetinghigh impact
Cruxal's analysis: Eiko LifeSciences Limited reported consolidated revenue from operations of 16.75 crore…
Read the full analysis - Eiko LifeSciences Limited schedules Board Meeting for August 12, 2026, to approve Q1 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Eiko LifeSciences Limited has issued a formal intimation regarding a Board of Directors…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.